BioNexus Gene Lab Corp. (BGLC)
0.25
-0.05 (-16.44%)
At close: Mar 28, 2025, 2:45 PM
BioNexus Gene Lab Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
| Revenue | 9.77M | 10.93M | 13.36M | 11.39M | 126.95K | 212.33K | 107.68K | n/a |
| Cost of Revenue | 8.44M | 9.67M | 11.17M | 9.67M | 71.07K | 183.56K | 28.87K | n/a |
| Gross Profit | 1.33M | 1.26M | 2.19M | 1.72M | 55.89K | 28.77K | 78.81K | n/a |
| Operating Income | -2.59M | -291.18K | 1.06M | 1.27M | -275.7K | 59.9K | -127.91K | -840 |
| Interest Income | n/a | 12.48K | 12.97K | 11.31K | n/a | n/a | n/a | n/a |
| Pretax Income | -2.61M | -303.66K | 1.04M | 1.26M | -275.7K | 59.9K | -119.41K | -835 |
| Net Income | -2.63M | -355.97K | 751.57K | 1.09M | -246.47K | 26.45K | -123.75K | -835 |
| Selling & General & Admin | 4.41M | 1.73M | 1.2M | 1.33M | 356.64K | 241.93K | 206.72K | 835.00 |
| Research & Development | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Expenses | -486.04K | -179.28K | -66.49K | -886.94K | -25.05K | 273.07K | n/a | n/a |
| Operating Expenses | 3.92M | 1.55M | 1.14M | 446K | 331.59K | -31.14K | 206.72K | 835.00 |
| Interest Expense | 13.93K | 12.48K | 12.97K | 11.31K | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 12.36M | 11.22M | 12.31M | 10.12M | 402.66K | 152.43K | 235.59K | 835.00 |
| Income Tax | 21.53K | 52.31K | 291.28K | 168.41K | -29.24K | 33.45K | 4.34K | -835 |
| Shares Outstanding (Basic) | 15.88M | 14.41M | 14.27M | 8.58M | 7.2M | 5.53M | 6.22M | 6.22M |
| Shares Outstanding (Diluted) | 15.88M | 14.41M | 14.27M | 8.58M | 7.2M | 5.53M | 6.22M | 6.22M |
| EPS (Basic) | -0.17 | -0.02 | 0.05 | 0.13 | -0.03 | 0.00 | -0.02 | -0.00 |
| EPS (Diluted) | -0.17 | -0.02 | 0.05 | 0.13 | -0.03 | 0.00 | -0.02 | -0.00 |
| EBITDA | -2.49M | -185.76K | 1.16M | 1.38M | -222.37K | 100.51K | -104.38K | n/a |
| Depreciation & Amortization | 108.42K | 105.42K | 108.22K | 101.6K | 53.33K | 40.61K | 15.03K | 835.00 |